Elamipretide data demonstrated improvement in mitochondrial function in pediatric cardiomyopathy
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of positive elamipretide data showing improvements in mitochondrial respiration and heart muscle function in tissue from failing human hearts at the International Society for Heart Research North American Section Meeting 2021.
Problems in energy production are well-characterized in pediatric and adult heart failure and postulated to be centrally involved in impaired cardiac function in these patients. In this study, mitochondria and muscle fibers from the explanted failing left ventricle were isolated from adult and pediatric patients undergoing cardiac transplant, post organ transplantation. The effects of elamipretide on mitochondrial respiration and muscle function were determined in the laboratory. Mitochondrial respiration was decreased in heart tissue from patients with pediatric cardiomyopathy compared to explanted tissue from non-failing hearts. Study findings showed that these impairments in respiration were significantly improved with elamipretide treatment in the pediatric hearts. The study also demonstrated that elamipretide treatment improved both contraction and relaxation in muscle fibers isolated from failing hearts of patients with dilated cardiomyopathy.
"This study builds upon our previously published findings that elamipretide improves mitochondrial and muscle fiber function in heart tissue isolated from the failing human heart. The observation of improved mitochondrial function from pediatric cardiomyopathy is very encouraging as there are currently no therapies that target mitochondrial dysfunction in this patient population. These data are consistent with our observed effects of elamipretide across other types of heart failure including idiopathic cardiomyopathy and metabolic (muscular dystrophy) cardiomyopathy" said Dr. Brian Stauffer, Chief of Cardiology at Denver Health Medical Center and Professor of Medicine/Cardiology at the University of Colorado Anschutz Medical Campus, who was the lead author on the study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.